Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.

Abstract

The purpose of this study was to generate lymphokine-activated killer cells via alternative pathways using combinations of biologic agents. Immunotherapy with the mouse anti-CD3 analogue combined with low-dose interleukin 2 (IL-2) and tumor necrosis factor alpha (TNF-alpha) was tested for in vivo antitumor efficacy against established pulmonary metastases… (More)

Topics

Cite this paper

@article{Yang1990SuccessfulCI, title={Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.}, author={Steven C. Yang and Kelsi Fry and E. A. Grimm and J A Roth}, journal={Archives of surgery}, year={1990}, volume={125 2}, pages={220-5} }